Intellia Therapeutics to Present at November Healthcare Investor Conferences

CAMBRIDGE, Mass., Nov. 02, 2017 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ: NTLA), a leading genome editing company focused on the development of curative therapeutics using CRISPR/Cas9 technology, will present at the following upcoming healthcare conferences in November:

Tuesday, November 7, 2017Credit Suisse 26th Annual Healthcare ConferenceWho: Tom Barnes, Ph.D., Senior Vice President, Innovation SciencesLocation: Scottsdale, ArizonaPresentation Time: 9:45am MST (11:45am EST)

Wednesday, November 15, 2017Jefferies London Healthcare ConferenceWho: John Leonard, M.D., Executive Vice President, R&DLocation: London, United KingdomPresentation Time: 8:40am GMT (2:40am EST)

Thursday, November 30, 2017Barclays Gene Editing/Therapy SummitWho: Nessan Bermingham, Ph.D., Chief Executive Officer and FounderLocation: New York, New York Presentation Time: 1:40pm EST

A live webcast of Intellia’s presentations will be accessible through the Events and Presentations page of the Investor Relations section of the company’s website at www.intelliatx.com. To access the webcasts, please log on to the Intellia website approximately 15 minutes prior to the start time to ensure adequate time for any software downloads that may be required. A replay of the webcast will be available on Intellia’s website for 14 days following each conference.

About Intellia TherapeuticsIntellia Therapeutics is a leading genome editing company focused on the development of proprietary, curative therapeutics using the CRISPR/Cas9 system. Intellia believes the CRISPR/Cas9 technology has the potential to transform medicine by permanently editing disease-associated genes in the human body with a single treatment course. The combination of deep scientific, technical and clinical development experience, along with its leading intellectual property portfolio, puts Intellia in a unique position to unlock broad therapeutic applications of the CRISPR/Cas9 technology and create a new class of therapeutic products. Learn more about Intellia Therapeutics and CRISPR/Cas9 at intelliatx.com; Follow us on Twitter @intelliatweets

Investor Contact:                                            Lindsey Trickett                                               Vice President, Investor Relations+1 857-285-6211                                              [email protected] 

Media Contact:Jennifer Mound SmoterSenior Vice President, External Affairs &Communications1 857-706-1071[email protected]

Source: Intellia Therapeutics, Inc.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Jefferies Starts Latigo Biotherapeutics (LTGO) at Buy
• Select Medical and Corewell Health Form Joint Venture to Build New Inpatient Rehabilitation Hospital in Southeast Michigan
• Kahuna Workforce Solutions Announces Strategic Partnership with Oracle to Connect Core HR Operations with Frontline Execution